key: cord-0687753-8uk0580m
authors: Molodtsov, Ivan A.; Kegeles, Evgenii; Mitin, Alexander N.; Mityaeva, Olga; Musatova, Oksana E.; Panova, Anna E.; Pashenkov, Mikhail V.; Peshkova, Iuliia O.; Alsalloum, Almaqdad; Asaad, Walaa; Budikhina, Anna S.; Deryabin, Alexander S.; Dolzhikova, Inna V.; Filimonova, Ioanna N.; Gracheva, Alexandra N.; Ivanova, Oxana I.; Kizilova, Anastasia; Komogorova, Viktoria V.; Komova, Anastasia; Kompantseva, Natalia I.; Kucheryavykh, Ekaterina; Lagutkin, Denis A.; Lomakin, Yakov A.; Maleeva, Alexandra V.; Maryukhnich, Elena V.; Mohammad, Afraa; Murugin, Vladimir V.; Murugina, Nina E.; Navoikova, Anna; Nikonova, Margarita F.; Ovchinnikova, Leyla A.; Panarina, Yana; Pinegina, Natalia V.; Potashnikova, Daria M.; Romanova, Elizaveta V.; Saidova, Aleena A.; Sakr, Nawar; Samoilova, Anastasia G.; Serdyuk, Yana; Shakirova, Naina T.; Sharova, Nina I.; Sheetikov, Saveliy A.; Shemetova, Anastasia F.; Shevkova, Liudmila V.; Shpektor, Alexander V.; Trufanova, Anna; Tvorogova, Anna V.; Ukrainskaya, Valeria M.; Vinokurov, Anatoliy S.; Vorobyeva, Daria A.; Zornikova, Ksenia V.; Efimov, Grigory A.; Khaitov, Musa R.; Kofiadi, Ilya A.; Komissarov, Alexey A.; Logunov, Denis Y.; Naigovzina, Nelli B.; Rubtsov, Yury P.; Vasilyeva, Irina A.; Volchkov, Pavel; Vasilieva, Elena
title: SARS-CoV-2-specific T cells and antibodies in COVID-19 protection: a prospective study
date: 2022-04-12
journal: Clin Infect Dis
DOI: 10.1093/cid/ciac278
sha: 28ba4c16428bd1aeb51f4d9d237b7f536dd567f7
doc_id: 687753
cord_uid: 8uk0580m

BACKGROUND: During the ongoing coronavirus disease COVID-19 pandemic, many individuals were infected with and have cleared the virus, developing virus-specific antibodies and effector/memory T cells. An important unanswered question is what levels of T cell and antibody responses are sufficient to protect from the infection. METHODS: In 5340 Moscow residents, we evaluated anti-SARS-CoV-2 IgM/IgG titers and frequencies of the T cells specific to the membrane, nucleocapsid, and spike proteins of SARS-CoV-2, using IFNγ ELISpot assay. Additionally, we evaluated the fractions of virus-specific CD4(+) and CD8(+) T cells using intracellular staining of IFNγ and IL2 followed by flow cytometry. We analyzed the COVID-19 rates as a function of the assessed antibody and T cell responses, using the Kaplan-Meyer estimator method, for up to 300 days post-inclusion. RESULTS: We showed that T cell and antibody responses are closely interconnected and are commonly induced concurrently. Magnitudes of both responses inversely correlated with infection probability. Individuals positive for both responses demonstrated the highest levels of protectivity against the SARS-CoV-2 infection. A comparable level of protection was found in individuals with antibody response only, while the T cell response by itself granted only intermediate protection. CONCLUSIONS: We found that the contribution of the virus-specific antibodies to protection against the SARS-CoV-2 infection is more pronounced than that of the T cells. The data on the virus-specific IgG titers may be instructive for making decisions in personalized health care and public anti-COVID-19 policies.

which were shown to protect from re-infection [4] [5] [6] [7] [8] . However, the antibody and T cell response levels 5 vary considerably from person to person and substantially decrease over time [9, 10] . These facts raise an 6

important question: what levels of T cell response and IgG titers are sufficient to protect from the 7 infection? The definitive answer requires a population level study of the immune response to SARS-CoV-8 2 followed by the tracing of infection rates. 9

Here, we report on a prospective study based on evaluation of the virus-specific Ig levels and virus-10 specific T cells in a cohort of 5,340 Moscow residents. Specifically, we evaluated the anti-SARS-CoV-2 11

IgM/IgG titers and the frequencies of the T cells specific to membrane (M), nucleocapsid (N), and spike 12 (S) proteins of SARS-CoV-2, using IFNγ ELISpot. Furthermore, we assessed the fractions of the virus-13 specific IFNγand IL2-producing CD4 + and CD8 + T cells using flow cytometry. Finally, we monitored 14 the participants for up to 300 days and analyzed the post-inclusion COVID-19 rates as a function of the 15 antibody and T cell response levels. 16

We found that the magnitudes of SARS-CoV-2-specific T cell and antibody responses inversely re-vaccination of individuals who were earlier vaccinated or who recovered from COVID-19. 23

Declaration. All participants provided written informed consent. The study was registered on 3

ClinicalTrials.gov (Identifier: NCT04898140). 4

Individuals enrolled in the study were Moscow residents above 18 years old who voluntarily visited 5

Moscow city clinics for routine testing for COVID-19 antibodies and agreed to participate. No specific 6 inclusion or exclusion criteria were applied. The Moscow State COVID-19 registry was used to extract 7 information about participants' vaccination statuses and previous PCR-confirmed Peripheral blood was collected into two 8-mL Vacutainer CPT tubes with sodium citrate (BD, USA). 9

Peripheral blood mononuclear cells (PBMC) were isolated according to the manufacturer's protocol 10 within two hours after venipuncture (for details, see Supplementary Material 1). For serum isolation, 11 peripheral blood was collected into S-Monovette 7.5-mL Z tubes (Sarstedt, Germany). 12 SARS-CoV-2-specific antibodies were evaluated using an automated CL-series chemiluminescent 13 immunoassay analyzer with compatible reagent kits (Mindray, China). The assay detects an integrated 14 pool of antibodies specific to full-length N protein, as well as receptor-binding-domain (RBD) fragment 15 of the S protein (see Supplement). According to the manufacturer, the assay units can be converted into 16 the WHO standard BAU/mL by dividing by 1.32 (for details, see Supplementary material 1). 17

Virus-neutralizing activity of plasma was analyzed with a microneutralization assay using a SARS-CoV-2 18 strain (hCoV-19/Russia/Moscow_PMVL-1/2020) in a 96-well plate and a 50% tissue culture infective 19 dose (TCID50) of 100 as described in [6] , with plasma dilutions of 10, 20, 40, 80, 160, 320, 640, and 20 1,280 times. 21

Flow cytometry was performed on freshly isolated PBMC stimulated with a mixture of SARS-CoV-2 22

PepTivator S, S1, S+, N, and M peptide pools (1 μg/mL each, Miltenyi Biotec, Germany). After 14-16 h 23

of stimulation, cells were stained with a panel of antibodies against surface markers and cytokines and 1 then analyzed with flow cytometry (Supplementary Figure 1) . Data were analyzed using FlowJo software 2 (BD Biosciences, USA) (for details, see Supplementary material 1). 3

IFNγ ELISpot assay was performed on freshly isolated PBMC using the IFNγ Single-Color ELISPOT kit 4 (CTL, USA). For each donor, five wells were tested without replicates: a negative control well without 5 stimulation, a positive control well non-specifically stimulated with 10 µg/mL phytohemagglutinin, and 6 three experimental wells stimulated with PepTivator peptide pools covering the M-, N-, or S-protein of 7 SARS-CoV-2. Spots were visualized and counted using an automated spot counter CTL ImmunoSpot 8

Analyzer and ImmunoSpot software (CTL, USA) (for details, see Supplementary Material 1). It should be 9

noted that there were no replicates in our ELISpot protocol; undoubtedly, it represents a limitation of the 10 study. However, we believe that the large number of samples analyzed allowed us to mitigate the 11 variability of the method. 12

Statistical analysis was performed with the Python3 programming language with numpy, scipy, pandas, 13 and lifelines packages (for details, see Supplementary Material 1). 14 Serology positivity thresholds were set according to the assay manufacturer's instructions at 10 AU/mL 15 for IgG and 1 Cutoff Index (COI) for IgM, respectively. For IFNγ ELISpot and flow cytometry assays, 16 positivity criteria were developed individually (see Supplementary Material 2). 17

In total, 5,340 individuals from the Moscow general population were included in the study. All of them 20

were tested for SARS-CoV-2-specific IgG/IgM titers, while virus-specific T cells in peripheral blood 21

were estimated for 156 participants using ELISpot, for 1,640 participants using flow cytometry, and for 22 1,629 participants using both assays ( Figure 1A) . The difference in these numbers resulted from cases in 23

which the peripheral blood amount was not enough to perform both T cell assays, or from which samples 1 were excluded from the analysis because of failed controls. Cohort recruitment lasted from October to 2 December 2020; the age and sex distribution of the participants is presented in Figure 1B Figure 1D . The cohort recruitment 7 took place before the onset of the public vaccination program in Moscow. However, among participants 8 enrolled there were 175 individuals who had participated in the Sputnik V vaccine clinical trial and who 9 thus had received either vaccine or placebo. 10

At the time of inclusion, 1,382 (26%) individuals were positive for SARS-CoV-2-specific IgM and 2,455 12 (46%) for IgG ( We analyzed the frequencies of the T cells specific to the M, N, and S proteins of SARS-CoV-2 in 19 peripheral blood, using the IFNγ ELISpot assay; as well, we analyzed the frequencies of IL2-and IFNγ-20 producing virus-specific CD4 + and CD8 + T cells, with flow cytometry. For this purpose, we used a We observed a strong correlation between the frequencies of SARS-CoV-2 -specific T cells detected with 7

ELISpot and those detected with flow cytometry; also, a strong correlation between IgG titers and T cell 8 frequencies was determined (Supplementary Figure 5) . This correlation was found in the cases of M-, N-, 9

and S-protein-specific T cells, as well as for different populations of CD4 + +T cells. 10

To evaluate the effects of antibody and T cell responses on susceptibility to SARS-CoV-2 infection, we Figure 3B) . 9

Surprisingly, the Q3 quantile, with infection chances in the intermediate range, also had VNA 10 significantly higher than Q1, demonstrating an absence of protectivity. There was no difference in VNA 11

between the Q1 and Q2 quantiles. fact that these titers were below the seropositivity cut-off. Moreover, we found significant virus-19 neutralizing activity among these individuals. Given the strong correlation between antibody and T cell 20 responses found in the study, the protection observed in these individuals might be T cell-dependent. We 21 surmise that this group may consist of individuals who developed a COVID-19-specific response after 22 previous asymptomatic infection [23, 24] , or after infection with either cross-reactive "common cold" 23 coronaviruses [11] or other pathogens [25, 26] . The low-level humoral response could nevertheless be 24

indicative of successful formation of memory B cells, as it is known that SARS-CoV-2 induces the 1 formation of durable B cell memory [27] [28] [29] . 2

Depending on estimated T cell and antibody responses, we split the participants into four groups and 3 analyzed the protection against the SARS-CoV-2 infection. Two groups were characterized by the highest 4 protection: individuals positive for both types of responses and those with antibody response only. 5

Apparently, these groups contain individuals with previous COVID-19 which had not been confirmed by 6 PCR for some reasons. It is noteworthy that even though the reinfection rates in these groups were very 7 small, few cases were still detected. Individuals with T cell response alone demonstrated intermediate 8 protection levels that nevertheless were higher than levels in individuals without either type of immunity. 9

Statistically significant protection was observed for N-and S-protein-specific T cell responses. 10

Individuals single-positive for these cellular response metrics had higher IgG titers than individuals 11 without either type of immunity, although the titers were below the positivity cut-off. Taken together, our 12 results demonstrated that antibodies better correlated with protection against the SARS-CoV-2 infection, 13

indicating that IgG evaluation is a more precise method for prediction of infection chances than virus- 

The authors declare no competing interests. 

SARS-CoV-2-specific T cell immunity in 2 cases of COVID-19 and SARS, and uninfected controls

Phenotype and kinetics of SARS-CoV-2

specific T cells in COVID-19 patients with acute respiratory distress syndrome

Immunogenicity of standard and extended dosing 7 intervals of BNT162b2 mRNA vaccine

A neutralizing human antibody binds to the N-terminal 9 domain of the Spike protein of SARS-CoV-2

The immunodominant and neutralization linear epitopes for 11 SARS-CoV-2

Safety and immunogenicity of an 13 rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: 14 two open, non-randomised phase 1/2 studies from Russia

Immune correlates analysis of the 16 mRNA-1273 COVID-19 vaccine efficacy clinical trial

Correlates of protection against symptomatic and 18 asymptomatic SARS-CoV-2 infection

Robust SARS-CoV-2-specific T cell immunity is 20 maintained at 6 months following primary infection

Evolution of immune responses to SARS-CoV-2 12

Public and Diverse Repertoire of Human T Cell Receptors

Assessment of protection against 7 reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a 8 population-level observational study

Re-infection with SARS-CoV-2 in Patients 10

Undergoing Serial Laboratory Testing

SARS-CoV-2 reinfection in patients negative for 12 immunoglobulin G following recovery from COVID-19

Establishment of an African green monkey 15 model for COVID-19 and protection against re-infection

Correlates of protection against SARS-CoV-2 in 17 rhesus macaques

SARS-CoV-2 infection protects against 19 rechallenge in rhesus macaques

Comparative Multi-Donor Study of IFNgamma 21 Secretion and Expression by Human PBMCs Using ELISPOT Side-by-Side with ELISA

Spread of endemic SARS-CoV-2 lineages 4 in Russia

The rise and spread of the SARS-CoV-2 AY

Clinical and immunological assessment of 8 asymptomatic SARS-CoV-2 infections

Intrafamilial Exposure to SARS-CoV-2 Associated 10 with Cellular Immune Response without Seroconversion

Virus-specific CD4(+) memory-phenotype T cells are 12 abundant in unexposed adults

Proteome-wide analysis of HIV-specific naive 14 and memory CD4(+) T cells in unexposed blood donors

Maturation and persistence of the anti-16 SARS-CoV-2 memory B cell response

Rapid generation of durable B cell memory to 18

SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence

Pattern of circulating SARS-CoV-2-21 specific antibody-secreting and memory B-cell generation in patients with acute COVID-19

Broad and strong memory CD4(+) and CD8(+) T cells 3 induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

Reduction and Functional Exhaustion of T Cells in

COVID-19)

SARS-CoV-2-specific T cell responses and 8 correlations with COVID-19 patient predisposition

Elevated exhaustion levels and reduced functional 10 diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients

Impaired Cytotoxic CD8(+) T Cell 13 Response in Elderly COVID-19 Patients

Recovery from acute SARS-CoV-2 infection 15 and development of anamnestic immune responses in T cell-depleted rhesus macaques

Rapid induction of antigen-specific CD4(+) T 20 cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA 21 vaccination